Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of polypeptide and its application in the preparation of anti-platelet aggregation medicine

An anti-platelet aggregation and platelet aggregation technology, which is applied in the field of medicine and biology, can solve the problems of increasing the risk of cerebral hemorrhage in patients and not seeing the activity of polypeptide A11, and achieve the effect of inhibiting platelet aggregation, inhibiting platelet aggregation, and seeing no toxic and side effects.

Active Publication Date: 2022-07-26
FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinical trials have shown that while vorapaxar inhibits platelet aggregation, it also increases the risk of cerebral hemorrhage in patients
[0004] At present, there is no report on the anti-platelet aggregation polypeptide A11 and its activity in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of polypeptide and its application in the preparation of anti-platelet aggregation medicine
  • A kind of polypeptide and its application in the preparation of anti-platelet aggregation medicine
  • A kind of polypeptide and its application in the preparation of anti-platelet aggregation medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] According to the method reported in the literature (La Face DM, Couture C, Anderson K, et al. Differential T cell signaling induced by antagonist peptide-MHC complexes and the associated phenotypic responses. J Immunol. 1997 Mar 1;158(5):2057–2064 .), the peptide A11 was synthesized using the method of solid-phase peptide synthesis. The synthesized peptides were purified by high performance liquid chromatography (HPLC), and the concentration was ≥95% (attached). figure 1 ). Subsequently, the amino acid sequence and molecular weight were determined by mass spectrometry (MS), and it was confirmed that the synthesized polypeptide was A11 (attached). figure 2 ).

[0031] A11 inhibits thrombin-induced human platelet aggregation in vitro.

[0032] (1) Healthy volunteers from platelets from the experimenter signed the informed consent for blood donation and were given certain nutritional subsidies. Venous whole blood was collected, apheresis platelets were separated by Ku...

Embodiment 2

[0039] A11 inhibits platelet clot retraction.

[0040] (1) The source of experimental human platelets is the same as that of Example 1.

[0041] (2) The specific implementation is as follows:

[0042] Platelet-rich plasma was diluted with Tyrode's Buffer A and quantified to 500 × 10 9 / L, take 200 μL of platelet-rich plasma into a siliconized transparent glass tube, and incubate at 37°C for 20 minutes. A11 was dissolved in DMSO to adjust the concentration to 200 mM. The experimental groups were: positive control group (Thrombin 0.2U / mL), negative control group (Control) and A11 experimental group. A11 with a final concentration of 1 mM was added to the experimental group, the same volume of DMSO was added to the positive control group and the negative control group as the experimental group, and incubated at 37°C for 20 minutes. After incubation, add thrombin with a final concentration of 0.2 U / mL to the positive control group and A11 experimental tube, mix well, and place...

Embodiment 3

[0045] Take the polypeptide A11, dissolve it with a small amount of DMSO, add water for injection as usual, finely filter it, and fill it with sterilization to prepare an injection solution.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-platelet aggregation polypeptide A11, which belongs to the field of medicine and biotechnology. The polypeptide A11 of the present invention is composed of 12 amino acids, has the sequence of the polypeptide of SEQ ID NO: 1, the molecular weight is 1262.24, and the sequence is Ser-Ile-Ser-Ser-Asn-Asn-Ser-Asn-Pro-Val-Glu- Asp. The polypeptide is not limited to inhibiting thrombin-induced platelet aggregation, and can be used to explore the effect and related functions of the polypeptide and other platelet activators (collagen, arachidonic acid, ADP, epinephrine, ristocetin, etc.) on platelets effects and can also be used to monitor existing antiplatelet therapy.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and relates to a polypeptide, in particular to an anti-platelet aggregation polypeptide A11, a preparation method thereof, a pharmaceutical composition composed of it as an active ingredient, and its use in the preparation of an anti-platelet medicine. Applications Background technique [0002] The incidence, mortality, morbidity and recurrence rates of cardiovascular and cerebrovascular diseases have been increasing year by year, which not only brings a heavy economic burden to patients, but also causes certain damage to their physiology and psychology, resulting in a decline in the quality of life of patients. . Activation of platelets is a central link in thrombosis, so antiplatelet therapy is very important in the management of cardiovascular disease. At present, clinical antiplatelet drugs still have bleeding risks, individual differences in efficacy and drug resistance. Ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/08A61K38/10A61P7/02
CPCC07K7/08A61K38/10A61P7/02
Inventor 孟照辉叶雨佳王博杨理宏万雯孙贵虎
Owner FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com